A phase I/II study of atacicept (TACI-Ig) to neutralize APRIL and BLyS in patients with refractory or relapsed multiple myeloma (MM) or active previously treated waldenstrom's macroglobulinemia (WM).

被引：9
|
作者：
Rossi, Jean-Francois
Moreaux, Jerome
Rose, Mikaelle
Picard, Marie
Ythier, Arnaud
Rossier, Ciara
Sievers, Eric
Klein, Bernard
机构：
[1] Univ Hosp, Unit Cellular & Gene Therapy, Montpellier, France
[2] Serono Int, Geneva, Switzerland
[3] Zymogenet Inc, Seattle, WA 98105 USA
来源：
BLOOD | 2006年 / 108卷 / 11期
关键词：
D O I：
10.1182/blood.V108.11.3578.3578
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3578
引用
收藏
页码：1022A / 1022A
页数：1
相关论文
共 50 条
  • [21] A Phase I/II Study of the Combination of Panobinostat and Carfilzomib in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Final Analysis of Second Dose Expansion
    Berdeja, Jesus G.
    Gregory, Tara B.
    Faber, Edward
    Matous, Jeffrey
    Hart, Lowell
    Mace, Joseph R.
    Arrowsmith, Edward R.
    Flinn, Ian W.
    BLOOD, 2016, 128 (22)
  • [22] Phase I/II dose-escalation study of daratumumab in patients with relapsed or refractory multiple myeloma
    Lokhorst, Henk M.
    Plesner, Torben
    Gimsing, Peter
    Nahi, Hareth
    Minnema, Monique
    Lassen, Ulrik Niels
    Krejcik, Jakub
    Laubach, Jacob
    Lisby, Steen
    Basse, Linda
    Richardson, Paul Gerard Guy
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [23] Phase II study of lenalidomide (Len), bortezomib (Bz), and dexamethasone (Dex) in patients (pts) with relapsed or relapsed and refractory multiple myeloma (MM)
    Anderson, K. C.
    Jagannath, S.
    Jakubowiak, A.
    Lonial, S.
    Raje, N.
    Schlossman, R.
    Munshi, N.
    Knight, R.
    Esseltine, D.
    Richardson, P. G.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [24] Phase I/II report from a Multicenter trial of perifosine (KRX-0401) plus bortezomib in patients with relapsed or Relapsed/Refractory multiple myeloma previously treated with bortezomib
    Richardson, Paul
    Jakubowiak, A.
    Wolf, J.
    Allerton, J.
    Zonder, J.
    Lonial, S.
    Krishnan, A.
    Densmore, J.
    Ghobrial, I.
    Colson, K.
    Kendall, T.
    Leister, C.
    Martineau, B.
    Hideshima, T.
    Facon, T.
    Sportelli, P.
    Gardner, L.
    Birch, R.
    Henderson, I. C.
    Anderson, K.
    BLOOD, 2007, 110 (11) : 354A - 355A
  • [25] A Phase I Study of Oral Melphalan Combined with LBH589 for Patients with Relapsed or Refractory Multiple Myeloma (MM).
    Berenson, James R.
    Yellin, Ori
    Boccia, Ralph V.
    Nassir, Youram
    Rothstein, Shellie
    Swift, Regina A.
    BLOOD, 2009, 114 (22) : 736 - 736
  • [26] Phase I Study of Carfilzomib in Patients (Pts) with Relapsed and Refractory Multiple Myeloma (MM) and Varying Degrees of Renal Insufficiency
    Badros, Ashraf Z.
    Vij, Ravi
    Martin, Thomas
    Zonder, Jeffrey A.
    Woo, Tina
    Wang, Zhengping
    Lee, Susan
    Wong, Alvin
    Niesvizky, Ruben
    BLOOD, 2009, 114 (22) : 1492 - 1492
  • [27] PRELIMINARY RESULTS OF A PHASE I/II STUDY OF CARFILZOMIB, LENALIDOMIDE, VORINOSTAT AND DEXAMETHASONE (QUAD) IN RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (MM)
    Bilotti, El
    Vesole, D.
    Richter, J.
    McNeill, A.
    Anand, P.
    Bednarz, U.
    Ivanovski, K.
    McBride, L.
    Raucci, L.
    Batra, V.
    Siegel, D.
    HAEMATOLOGICA, 2013, 98 : 323 - 324
  • [28] A Phase I/II Study of Pomalidomide and Dexamethasone with Growth Factor Support in Patients with Relapsed/Refractory Multiple Myeloma
    Manasanch, Elisabet E.
    Lee, Hans C.
    Patel, Krina K.
    Weber, Donna M.
    Lee, Hun Ju
    Thomas, Sheeba K.
    Chen, Wendy
    Oriabure, Onyeka
    Badillo, Maria
    Graham, Vivian
    Lei, Feng
    McCarthy, Magda S.
    Orlowski, Robert Z.
    Wang, Michael
    BLOOD, 2017, 130
  • [29] Tanespimycin plus bortezomib in patients with relapsed and refractory multiple myeloma: Final results of a phase I/II study
    Richardson, P. G.
    Chanan-Khan, A.
    Lonial, S.
    Krishnan, A.
    Carroll, M.
    Alsina, M.
    Albitar, M.
    Berman, D.
    Kaplita, S.
    Anderson, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [30] Phase I/II study of weekly PM00104 (Zalypsis®) in patients with relapsed/refractory multiple myeloma
    Ocio, Enrique M.
    Oriol, Albert
    Blade, Joan
    Teruel, Ana I.
    Martin, Jesus
    de la Rubia, Javier
    Gutierrez, Norma C.
    Rodriguez Diaz-Pavon, Jose
    Martinez Gonzalez, Sara
    Coronado, Cinthya
    Fernandez-Garcia, Eva M.
    Siguero Gomez, Mariano
    Fernandez-Teruel, Carlos
    San Miguel, Jesus
    BRITISH JOURNAL OF HAEMATOLOGY, 2016, 172 (04) : 625 - 628
12345